Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations

Broesby‐Olsen, Sigurd; Vestergaard, Hanne; Mørtz, Charlotte G.; Jensen, Bjarne Astrup; Havelund, Troels; Hermann, Andreas; Siebenhaar, Frank; Møller, Michael; Kristensen, Thomas Kielsgaard; Bindslev‐Jensen, Carsten

doi:10.1111/all.13237

Cited by 95 publications

(72 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In any case this additional property of omalizumab opens the way to additional applications of the drug. In particular, all those conditions in which a risk of anaphylaxis exists, such as mastocytosis , allergen immunotherapy , drug desensitization, may benefit from omalizumab treatment.…”

Section: Discussionmentioning

confidence: 99%

Omalizumab dampens type 2 inflammation in a group of long‐term treated asthma patients and detaches IgE from FcεRI

et al. 2018

View full text Add to dashboard Cite

Even if omalizumab is broadly used in the treatment of severe, allergic asthma, the immunological effects in long-term treated patients have not been fully elucidated. To this aim, a cohort of 15 allergic asthmatic patients treated with omalizumab for at least three years was compared with 12 allergic asthma patients treated with standard therapy. Omalizumab treated asthmatic patients showed lower frequencies of circulating plasmacytoid DCs, and lower CD154 expression on CD4 T-helper cells than the control group. Moreover, basophils and DCs from omalizumab-treated patients had lower surface expression of IgE compared to the control group. In a longitudinal evaluation of two patients that started omalizumab treatment, we show that FcεRI free of IgE were evident on basophils just after four weeks of drug administration. Finally, in vitro experiments with basophils obtained from healthy donors confirm that omalizumab is able to detach IgE from high affinity IgE receptors. Collectively these data indicate that long-term omalizumab treatment dampens type 2 inflammation acting on different cell types that play a pivotal role in the pathogenesis of allergic asthma. Moreover, we have identified a further mechanism of action of omalizumab, such as the ability to detach IgE from its receptor.Keywords: asthma r basophils r FcεRI r IgE r omalizumab Additional supporting information may be found online in the Supporting Information section at the end of the article.

show abstract

Section: Discussionmentioning

confidence: 99%

Omalizumab dampens type 2 inflammation in a group of long‐term treated asthma patients and detaches IgE from FcεRI

et al. 2018

View full text Add to dashboard Cite

show abstract

“…184,187 Novel data arising from a long pipeline of cytokine and chemokine receptor targeting drugs will lead to additional treatment options and change the landscape of therapeutics in other atopic diseases including food allergy, chronic rhinosinusitis with nasal polyps, 12,188 and systemic mastocytosis. 189 Biologics may also increase efficacy and safety of AIT.…”

Section: Treatment Of Allergic Diseases With Biologicsmentioning

confidence: 99%

Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care

Breiteneder

Diamant

Eiwegger

et al. 2019

Allergy

View full text Add to dashboard Cite

This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. AbstractThe specialties of allergy and clinical immunology have entered the era of precision medicine with the stratification of diseases into distinct disease subsets, specific diagnoses, and targeted treatment options, including biologicals and small molecules.This article reviews recent developments in research and patient care and future trends in the discipline. The section on basic mechanisms of allergic diseases summarizes the current status and defines research needs in structural biology, type 2 inflammation, immune tolerance, neuroimmune mechanisms, role of the microbiome and diet, environmental factors, and respiratory viral infections. In the section on diagnostic challenges, clinical trials, precision medicine and immune monitoring Zuzana Diamanthttps://orcid.org/0000-0003-0133-0100Thomas Eiwegger https://orcid.org/0000-0002-2914-7829Wytske J. Fokkens https://orcid.org/0000-0003-4852-229X

show abstract

“…Moreover, the ability of omalizumab to detach prebound IgE from their receptors opens the way to additional applications in those clinical conditions in which degranulation of basophils and mast cells must be limited to prevent anaphylaxis. In this direction, it is not surprising that omalizumab works fine in mastocytosis , allergen immunotherapy , drug desensitization , and may be a promising option also for idiopathic nonhistaminergic acquired angioedema .…”

Section: Chronic Spontaneous Urticariamentioning

confidence: 99%

Biologicals targeting type 2 immunity: Lessons learned from asthma, chronic urticaria and atopic dermatitis

et al. 2019

View full text Add to dashboard Cite

During the last decades, progression of research has led to great achievements for treatment and therapy of several disabling disorders, particularly in the field of chronic inflammatory diseases. The increased knowledge of the molecular mechanisms operating in such diseases has represented the first step in this process, and the discovery of molecules able to interfere with the natural history of the diseases, has been the second. This review is focused on the effects of biologics on type 2 diseases such as asthma, chronic urticaria and atopic dermatitis, both biologics just approved for clinical application and also those that are currently undergoing clinical trials. We will also discuss aspects and emphasize clinical trials and recently published studies, as well as research that is currently in the progress, which will be highly relevant for basic immunologists. Likewise, we will cover aspects that are pertinent for clinical immunologists and highlight translational studies that are evaluating novel biologicals in animal models.Keywords: atopic dermatitis r bronchial asthma r chronic urticaria r precision medicine

show abstract

Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations

Abstract: Omalizumab appears to be a promising treatment option in SM, effectively preventing anaphylaxis and improving chronic MC mediator-related symptoms, insufficiently controlled by conventional therapy. Controlled studies are needed to substantiate findings.

Cited by 95 publications

References 23 publications

Omalizumab dampens type 2 inflammation in a group of long‐term treated asthma patients and detaches IgE from FcεRI

Omalizumab dampens type 2 inflammation in a group of long‐term treated asthma patients and detaches IgE from FcεRI

Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care

Biologicals targeting type 2 immunity: Lessons learned from asthma, chronic urticaria and atopic dermatitis

Contact Info

Product

Resources

About